The investment bank said it views atacicept as "largely de-risked, with a line of sight to commercialization starting next year." It added that feedback from Key Opinion Leaders indicates ...

Atacicept is more disease-modifying, while sibeprenlimab offers better immediate kidney protection; both have comparable safety profiles. Sibeprenlimab may hit the market 6 months earlier than ...

The decline was attributed to new information released by Otsuka regarding its drug sibeprelimab, which is anticipated to be a direct competitor to Vera's atacicept. Analyst Liisa Bayko of ...

On track to announce the primary endpoint result from the atacicept pivotal Phase 3 ORIGIN trial in IgA Nephropathy (IgAN) in 2Q 2025; BLA submission to the U.S. FDA for accelerated approval ...

Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on March 6, 2025, the Compensation Committee granted inducement awards consisting of a non-qualified stock option to purchase 51,500 shares ...